Who are Thiocolchicoside+Ketoprofen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eperisone hydrochloride and Diclofenac sodium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thiocolchicoside-ketoprofen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Thiocolchicoside+Ketoprofen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thiocolchicoside+Ketoprofen (Thiocolchicoside+Ketoprofen) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscle relaxant + NSAID combination. Area: Musculoskeletal/Pain Management.

phase 3 Muscle relaxant + NSAID combination GABA-A receptor (thiocolchicoside); COX-1/COX-2 (ketoprofen) Musculoskeletal/Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Thiocolchicoside+Ketoprofen (Thiocolchicoside+Ketoprofen) — Sanofi. Thiocolchicoside reduces muscle spasticity through GABA-A receptor modulation, while ketoprofen inhibits cyclooxygenase enzymes to reduce inflammation and pain.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Thiocolchicoside+Ketoprofen TARGET	Thiocolchicoside+Ketoprofen	Sanofi	phase 3	Muscle relaxant + NSAID combination	GABA-A receptor (thiocolchicoside); COX-1/COX-2 (ketoprofen)
Eperisone hydrochloride and Diclofenac sodium	Eperisone hydrochloride and Diclofenac sodium	Eisai Co., Ltd.	phase 3	Muscle relaxant + NSAID combination	Monoamine reuptake (eperisone); COX-1/COX-2 (diclofenac)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscle relaxant + NSAID combination class)

Eisai Co., Ltd. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thiocolchicoside+Ketoprofen — Competitive Intelligence Brief. https://druglandscape.com/ci/thiocolchicoside-ketoprofen. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing